AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to ...

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often ...

In 2025, Turbine took the first steps in opening its powerful cell simulation platform to the wider drug development ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...